// App-Quantinova.ai

425 : Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.

Researchers

Presenter

  • Norihiko Tsuchiya

Principal Investigators

  • Yoshiaki Yamamoto

  • Hirotsugu Uemura

  • Hiro-Omi Kanayama

  • Masatoshi Eto

  • Hideaki Miyake

  • Thomas Powles

  • Mizuki Yoshida

  • Yuichiro Koide

  • Yoshiko Umeyama

  • Alessandra Di Pietro

  • Yoshihiko Tomita

Medical Centers

  • Department of Neurosurgery, Yamagata University Faculty of Medicine, Yamagata, Japan

  • Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan

  • Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan

  • Department of Urology, Graduate School, The University of Tokushima, Tokushima, Japan

  • Department of Surgery and Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

  • Department of Neurosurgery, Yamagata University Faculty of Medicine, Yamagata, Japan

  • Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomews Hospital, London, United Kingdom

  • Pfizer Japan, Tokyo, Japan

  • Pfizer Inc, Milan, Italy

  • Nigata University Graduate School of Medical and Dental Sciences, Japan

Locations

  • Japan

  • United Kingdom

  • Italy

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • Cisplatin

  • Avelumab

  • SP263

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02603432

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved